Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction, lung inflammation, limited expiratory flow with subsequent lung hyperinflation, and increasing frequency and severity of exacerbations. Standard maintenance pharmacotherapy for COPD aims to improve symptoms and quality of life while preventing harmful exacerbations. Treatment comprises various combinations of bronchodilators (long-acting beta2-agonists and long-acting muscarinic antagonists) and inhaled corticosteroids. A drug utilization study is being prepared to understand the prescription patterns of COPD drugs across Canada and determine if they align with drug program policies and clinical practice guidelines.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.